A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Phase 1
Recruiting
- Conditions
- Hemostatic DisordersLymphoproliferative DisordersMultiple MyelomaNeoplasmsHematologic DiseasesImmunoproliferative DisordersCardiovascular DiseasesParaproteinemiasNeoplasms, Plasma CellNeoplasms by Histologic Type
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- OriCell Therapeutics Co., Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT06271252
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
Phase 1
Recruiting
- Conditions
- Relapsed and/or Refractory Multiple Myeloma
- Interventions
- Biological: OriCAR-017
- First Posted Date
- 2023-12-27
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- OriCell Therapeutics Co., Ltd.
- Target Recruit Count
- 83
- Registration Number
- NCT06182696
- Locations
- 🇨🇳
Beijing GoBroad Hospital, Beijing, China
🇨🇳The First Affiliated Hospital College of Medicine Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Tongji Hospital of Tongji University, Shanghai, China
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Phase 1
Recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biological: Ori-C101
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- OriCell Therapeutics Co., Ltd.
- Target Recruit Count
- 105
- Registration Number
- NCT05652920
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳The first hospital of Jilin University, Changchun, Jilin, China
© Copyright 2025. All Rights Reserved by MedPath